a16z | Big Ideas in 2024: Democratizing “Miracle Drugs” with Julie Yoo @a16z | Uploaded December 2023 | Updated October 2024, 27 minutes ago.
In 2023, a wave of therapies hailed as miracle drugs — including GLP-1’s and curative cell and gene therapies — had a profound impact in patients’ lives.
With 3.6 million prescription claims for GLP-1s in 2022, the question arises: Can innovators establish a sustainable approach to bring these groundbreaking drugs to market without causing financial strain or system breakdown?
Julie Yoo, General Partner at Andreessen Horowitz, shares a compelling big idea for 2024: Democratizing “Miracle Drugs”.
Timecodes:
00:00 - Big Ideas in Tech 2024
01:39 - Democratizing “Miracle Drugs”
02:35 - How a GPL-1 works and the potential impact of the drug
08:32 - Curative cell and gene therapies
11:21 - Drug costs and insurance systems
15:16 -The changes needed to enable drug access
17:36 - What solutions are being built?
20:48 - Policy, the FDA, and CMS
Resources:
View all 40+ big ideas: a16z.com/bigideas2024
Find Julie on X: twitter.com/julesyoo
Stay Updated:
Find a16z on Twitter: twitter.com/a16z
Find a16z on LinkedIn: linkedin.com/company/a16z
Subscribe on your favorite podcast app: a16z.simplecast.com
Follow our host: twitter.com/stephsmithio
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
In 2023, a wave of therapies hailed as miracle drugs — including GLP-1’s and curative cell and gene therapies — had a profound impact in patients’ lives.
With 3.6 million prescription claims for GLP-1s in 2022, the question arises: Can innovators establish a sustainable approach to bring these groundbreaking drugs to market without causing financial strain or system breakdown?
Julie Yoo, General Partner at Andreessen Horowitz, shares a compelling big idea for 2024: Democratizing “Miracle Drugs”.
Timecodes:
00:00 - Big Ideas in Tech 2024
01:39 - Democratizing “Miracle Drugs”
02:35 - How a GPL-1 works and the potential impact of the drug
08:32 - Curative cell and gene therapies
11:21 - Drug costs and insurance systems
15:16 -The changes needed to enable drug access
17:36 - What solutions are being built?
20:48 - Policy, the FDA, and CMS
Resources:
View all 40+ big ideas: a16z.com/bigideas2024
Find Julie on X: twitter.com/julesyoo
Stay Updated:
Find a16z on Twitter: twitter.com/a16z
Find a16z on LinkedIn: linkedin.com/company/a16z
Subscribe on your favorite podcast app: a16z.simplecast.com
Follow our host: twitter.com/stephsmithio
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
